HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s stock price fell 3.2% on Friday . The stock traded as low as $2.98 and last traded at $2.98. Approximately 100 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 904 shares. The stock had previously closed at $3.08.
HLS Therapeutics Stock Performance
The company has a 50 day simple moving average of $3.11 and a 200 day simple moving average of $3.24.
About HLS Therapeutics
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
